Aytu BioPharma projects $6M-$7M in quarterly sales and marketing spending amid rising EXXUA prescription volumes. Aytu BioPharma outlined a $6M-$7M quarterly sales and marketing expenditure range for fiscal Q3 2026. The company reported over 920 EXXUA prescriptions in Apri
Inovio Pharmaceuticals confirms financial runway through Q1 2027 as its lead drug candidate nears October 2026 regulatory decision. Inovio Pharmaceuticals announced its cash runway will extend into Q1 2027, providing financial stability as it advances INO-3107 toward a reg
Traders remain cautious as the currency pair stabilizes after six consecutive sessions of gains before key trade discussions. The USD/CAD pair traded steady around 1.3700 in Asian hours Thursday, pausing after six straight days of gains. Market participants adopted a wait-
PBOC sets daily USD/CNY reference rate below Reuters poll estimate, signaling modest depreciation pressure on the yuan. The People’s Bank of China set the USD/CNY reference rate at 6.8401 for Thursday’s session, down from 6.8426 the previous day but weaker than the 6.7888
PBOC sets USD/CNY rate at 6.8401 The PBOC has set the USD/CNY reference rate for today at 6.8401. This rate allows the yuan to fluctuate within a +/- 2% range. Standard Chartered notes suspected Japanese FX intervention totalling around $65 billion has shif
Investors hold positions ahead of key US retail data and high-stakes trade discussions between US and Chinese leaders. The USD/JPY pair remains unchanged at 157.85 in early Asian trading on Thursday. Market participants are adopting a cautious stance before the US-China su
Finance minister cites excessive won swings and Samsung labor strike as growing economic risks amid external uncertainty. South Korea’s finance minister stated the Korean won’s volatility has exceeded levels justified by economic fundamentals. The currency is expected to s
Oil prices retreat ahead of high-stakes US-China talks amid tariff reduction talks and geopolitical tensions in the Middle East. West Texas Intermediate crude fell to $96.80 per barrel in Asian trading, extending a two-day decline as investors awaited a critical meeting be
Longeveron outlines a new asset-light partnering model and sets an August 2026 timeline for its ELPIS II trial readout. Longeveron announced a strategic shift to an asset-light partnering model during its Q1 2026 earnings call. The move follows a comprehensive review of th
The medical imaging firm forecasts $39M in 2026 revenue as it prepares for a new AMA CPT code effective January 1, 2027. QT Imaging Holdings expects to generate $39M in revenue for 2026, reflecting progress in commercialization and regulatory expansion. The outlook aligns